Conference Coverage

Reports from professional meetings related to NHL.
Advances in Non-Hodgkin's Lymphoma (NHL) Treatment
Conference Dates: September 10, 2004 Conference Location: Audioconference Sponsoring Group: National Marrow Donor Program, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research Conference Web Page ..
Modulating IL-2 for Non-Hodgkins' Lymphoma (NHL)
Faculty Disclosure: Michael A. Caligiuri, M.D. This presentation by Dr. Caligiuri discusses off-label use of IL-2 for the treatment of NHL. Presenter: Michael A. Caligiuri, M.D. Affiliation: James Cancer Hospital ..
Proton Therapy in the Management of Non-Hodgkin Lymphoma
Presenter: Bradford Hoppe, MD Presenter's Affiliation: University of Florida Background Non-Hodgkin Lymphoma is a heterogeneous disease with 66,000 new cases each year The disease involves different lymphoid regions of the ..
CHEOP (Chop + Etoposide): the New Standard Regimen for Younger Patients with Low Risk (Low LDH) Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Michael G. Pfreundlschuh Presenter's Affiliation: Type of Session: Scientific Background Low Risk (normal LDH)aggressive NHL has classically been treated with CHOP chemotherapy given on a 21 day dosing schedule. ..
Long term follow up of an Alemtuzumab (CAMPATH-1H) containing reduced intensity Allogeneic Transplant Regimen for Non-Hodgkins Lymphoma (NHL)
Presenter: Emma MorrisPresenter's Affiliation: UK Collaborative Group, United KingdomType of Session: ScientificBackground Campath is an antibody that targets CD 52 which is a T cell marker. Campath has been studied ..
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)
This presentation discusses the off-label use of rituximab for the treatment of indolent NHL. Presenter: H.S. HochsterPresenter's Affiliation: ECOG/CALGBType of Session: ScientificBackground Indolent lymphomas (IL), as the name implies, have ..
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report
Presenter: Milone, G.Presenter's Affiliation: Instituto de Investigaciones Hematologicas, Buenos Aires, ArgentinaType of Session: ScientificBackground Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated ..
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report
Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated successfully with chemotherapy as well as immunotherapy with or without linked radionuclides. Fludarabine (F) ..
Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial.
Presenter: David Eilender Presenter's Affiliation: Wayne State University Type of Session: Poster Background Both chemotherapy (CHT) and radiation therapy (RT) are used in the treatment of non-Hodgkin's lymphoma (NHL). It ..
Early Restaging Positron Emmision Tomography (PET) with 18F-Fluorodeoxyglucose (18FDG)Predicts Outcome in Patients with Aggressive Non-Hodgkin's Lymphoma (NHL)
Presenter: Karoline Spaepen Affiliation: Leuven, Belgium Background Positron Emission Tomography (PET) with FDG (a radiolabeled sugar molecule) is a nuclear medicine study that is able to detect areas of active ..
High Levels of Soluble CD20 (sCD20) in patients with Non-Hodgkin's Lymphoma (NHL): Correlation with Clinical Behavior and Contrast with Patients with Hodgkin's Disease (HD)
Presenter: M. Albitar Presenter's Affiliation: MD Anderson Cancer Center, Texas Type of Session: Scientific Background CD20 is a Glycoprotein transmembrane receptor found on mature B-cells. Differences in the levels of ..
Long Term Follow Up of a Phase II study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Aggressive Non-Hodgkins Lymphoma (NHL)
Presenter: J.M. VosePresenter's Affiliation: University of Nebraska Medical CenterType of Session: PosterBackground Standard therapy for NHL is combination chemotherapy with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) Rituxan, a mouse/human anti CD 20 antibody has ..
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study
Presenter: Mathias J. Rummel MD, PhD Presenter's Affiliation: Universitaetsklinik, Giessen, Germany Background There are about 25,000 new cases of indolent B-cell lymphoma and mantle cell lymphoma per year, with a ..

News
PTSD Symptoms Persist in Some Long-Term NHL Survivors

Oct 13, 2011 - More than one third of the long-term survivors of non-Hodgkin's lymphoma experience persistence or worsening of the symptoms of post-traumatic stress disorder, according to a study published online Oct. 10 in the Journal of Clinical Oncology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.


OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More



OncoLink Cancer Treatment and Resources